Edition:
United Kingdom

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

8.07USD
14 Dec 2017
Change (% chg)

$0.10 (+1.25%)
Prev Close
$7.97
Open
$7.97
Day's High
$8.11
Day's Low
$7.95
Volume
102,166
Avg. Vol
55,104
52-wk High
$8.11
52-wk Low
$4.60

Chart for

About

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1)... (more)
No analyst recommendations are available for .

Overall

Beta: 0.08
Market Cap(Mil.): $399.48
Shares Outstanding(Mil.): 56.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​ Source text for Eikon: Further company coverage:

30 Nov 2017

BRIEF-Sinovac reports Q4 earnings per share $0.08

* Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results

22 Nov 2017

BRIEF-Sinovac Biotech receives delisting determination letter from Nasdaq

* Sinovac Biotech announces receipt of delisting determination letter from Nasdaq Source text for Eikon: Further company coverage:

03 Nov 2017

BRIEF-Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share

* Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share

29 Sep 2017

BRIEF-Sinovac Biotech preliminary phase III data shows Varicella vaccine was 87.1 pct efficacious against Chickenpox ​

* Sinovac reports preliminary top-line results from phase III clinical trial for Varicella vaccine candidate against Chickenpox

25 Sep 2017

BRIEF-Sinovac Biotech announces certain updates relating to delayed filing of annual report on form 20-F

* Sinovac Biotech announces certain updates relating to delayed filing of annual report on form 20-F

14 Aug 2017

BRIEF-Sinobioway consortium provides update on Sinovac Biotech acquisition

* Sinobioway consortium provides update on acquiring Sinovac Biotech at the purchase price of $8 per share

10 Aug 2017

BRIEF-Shandong Sinobioway's consortium makes an offer to take Sinovac Biotech private

* Says its consortium offers to buy Sinovac Biotech Ltd at $8 per share to take it private

28 Jun 2017

BRIEF-Sinovac Biotech enters into agreement for going-private transaction

* Sinovac Biotech Ltd enters into definitive agreement for going-private transaction

26 Jun 2017

Competitors

Earnings vs. Estimates